• Martin Aringer, Dirk Koschel, Andreas Krause, Udo Schneider, and Sven Gläser.
• Universitätsklinikum Carl Gustav Carus Dresden, Medizinische Klinik und Poliklinik III, Bereich Rheumatologie.
• Dtsch. Med. Wochenschr. 2022 Feb 1; 147 (4): 179186179-186.

AbstractSystemic Sclerosis with Interstitial Lung Disease (SSc-ILD) is associated with an increased risk of morbidity and mortality. Because of a lack of approved medications that can effectively influence SSc-ILD disease course, there is a need for new therapeutic options. Treatment with immunomodulatory therapies as well as with autologous stem cell transplant is being further investigated in current clinical studies. Recently, a phase III study demonstrated the positive effect of the antifibrotic agent nintedanib on the loss of lung volume and thus disease progression in patients with SSc-ILD. Due to its synergistic mechanism of action, combination therapy with nintedanib and mycophenolate could be a complementary treatment approach for SSc-ILD in the future.The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commecial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/).

24 keywords...

hide…